Ionis’ Latest Attempt To Weaponize Antisense Against Cancer – Seeking Alpha

Seeking AlphaIonis’ Latest Attempt To Weaponize Antisense Against CancerSeeking AlphaCancer-causing mutations in the KRAS gene have been studied for 30 years yet no direct inhibitor of mutant KRAS enzyme has entered clinical trials. Earlier generation antisense against cancer targets have not emerged from clinical trials. Most of those …Goldman Sachs Downgrades Ionis Pharmaceuticals Inc to Sell with Price Target $25Money Flow Index & TrendsIonis Pharmaceuticals, Inc. (NASDAQ:IONS) current consensus investment analysts is to HoldThe Independent Republicall 30 news articles »

Read More

Ionis’ Latest Attempt To Weaponize Antisense Against Cancer – Seeking Alpha

Seeking AlphaIonis’ Latest Attempt To Weaponize Antisense Against CancerSeeking AlphaCancer-causing mutations in the KRAS gene have been studied for 30 years yet no direct inhibitor of mutant KRAS enzyme has entered clinical trials. Earlier generation antisense against cancer targets have not emerged from clinical trials. Most of those …Ionis Pharmaceuticals, Inc. (IONS) recently sold by insider BENNETT C FRANKPost AnalystIonis Pharmaceuticals, Inc. (NASDAQ:IONS) current consensus investment analysts is to HoldThe Independent Republicall 29 news articles »

Read More

Bio-Path Holdings Reports Full Year 2016 Financial Results – GlobeNewswire (press release)

HuronReportBio-Path Holdings Reports Full Year 2016 Financial ResultsGlobeNewswire (press release)HOUSTON, March 15, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer …Bio-Path Holdings to Present at the Oppenheimer 27th Annual …PharmiWeb.com (press release)The Bio-Path Holdings Inc (BPTH) to Release Earnings on TuesdayPetro Global News 24$-0.03 EPS Expected for Bio-Path Holdings (BPTH), CSA HOLDINGS (CSAX) SI Increased By 38.82%HuronReportFiscal Standard -Equities.com -UK Market Newsall 14 news articles »

Read More

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference – EconoTimes

HuronReportBio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare ConferenceEconoTimesHOUSTON, March 14, 2017 — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today …Bio-Path Holdings’ (BPTH) CEO Peter Nielsen on Q4 2016 Results – Earnings Call TranscriptSeeking Alpha$-0.03 EPS Expected for Bio-Path Holdings (BPTH), CSA HOLDINGS (CSAX) SI Increased By 38.82%HuronReportThe Bio-Path Holdings Inc (BPTH) to Release Earnings on TuesdayPetro Global News 24all 18 news articles »

Read More

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference – GlobeNewswire (press release)

HuronReportBio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare ConferenceGlobeNewswire (press release)HOUSTON, March 14, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer …Bio-Path Holdings Reports Full Year 2016 Financial ResultsYahoo FinanceBio-Path Holdings’ (BPTH) CEO Peter Nielsen on Q4 2016 Results – Earnings Call TranscriptSeeking AlphaThe Bio-Path Holdings Inc (BPTH) to Release Earnings on TuesdayPetro Global News 24Equities.com -The De Soto Edgeall 18 news articles »

Read More

$4.1M Nant Investment in Benitec Supports Joint Antisense RNA Program for HNSCC – Genetic Engineering & Biotechnology News

$4.1M Nant Investment in Benitec Supports Joint Antisense RNA Program for HNSCCGenetic Engineering & Biotechnology NewsIn December Benitec confirmed that the collaboration would focus on a Phase II-stage DNA plasmid that produces an epidermal growth factor receptor-silencing antisense RNA (EGFR-AS) for treating head and neck squamous cell carcinoma (HNSCC).and more »

Read More

Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on … – Yahoo Finance

Is storiesBio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on …Yahoo FinanceHOUSTON, March 13, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, …BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD DisclosureMarket ExclusiveBio-Path Holdings Inc (BPTH) Scheduled to Post Earnings on TuesdayThe Cerbat GemBio-Path Holdings Inc. (BPTH) Moves Higher on Volume Spike for March 09Equities.comall 19 news articles »

Read More

Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on … – Nasdaq

Bio-Path Holdings Announces Rescheduled Date and Time of Fourth Quarter and Full Year 2016 Financial Results on …NasdaqHOUSTON, March 13, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer …

Read More

Bio-Path Holdings Announces Rescheduled Date and Time of … – EconoTimes

Is storiesBio-Path Holdings Announces Rescheduled Date and Time of …EconoTimesEconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical …Bio-Path Holdings to Present Data at the 2017 AACR Annual MeetingGlobeNewswire (press release)BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD DisclosureMarket ExclusiveBio-Path Holdings Inc (BPTH) Scheduled to Post Earnings on TuesdayThe Cerbat GemEquities.comall 19 news articles »

Read More

Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting – EconoTimes

Is storiesBio-Path Holdings to Present Data at the 2017 AACR Annual MeetingEconoTimesHOUSTON, March 10, 2017 — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today …BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD DisclosureMarket ExclusiveBio-Path Holdings Inc. (BPTH) Soars 8.12% on March 10Equities.comBio-Path Holdings, Inc. (BPTH) Rating Increased to Hold at Zacks Investment ResearchPetro Global News 24Fiscal Standardall 14 news articles »

Read More

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s Growing And Robust Pipeline – StockNewsUnion

Is storiesIdera Pharmaceuticals Inc (NASDAQ:IDRA)’s Growing And Robust PipelineStockNewsUnionThe firm, a leader in antisense technology, has advanced a third Generation Antisense technology base, which is anticipated to be introduced in H2 2017. Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biopharma firm advancing novel nucleic …Today Idera Pharmaceuticals, Inc. (IDRA) Cut to Hold at Zacks Investment ResearchDailyQuintNews review of 2 biotech stocks: Bioverativ Inc. (NASDAQ:BIVV), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)The Voice RegistrarBrokers Issue New Targets On Idera Pharmaceuticals, Inc. (IDRA)Fiscal Standardall 44 news articles »

Read More

OPKO’s oligonucleotid to treat dravet syndrome receives EU orphan drug designation – pharmabiz.com

Wolcott DailyOPKO’s oligonucleotid to treat dravet syndrome receives EU orphan drug designationpharmabiz.comAntagoNAT, anti-Natural Antisense Transcripts, is an OPKO platform technology in which single strand oligonucleotide molecules are designed to interfere with regulatory gene expression in order to enhance production of endogenous functional proteins.Opko Health (NASDAQ:OPK) subsidiaries, received notification from EU designating OPKO’s AntagoNATBenchmark Monitorall 22 news articles »

Read More

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 – Yahoo Finance

Is storiesBio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017Yahoo FinanceHOUSTON, March 09, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, …Bio-Path Holdings Inc. (BPTH) Soars 12.51% on March 09Equities.comBio-Path Holdings, Inc. (BPTH) Rating Increased to Hold at Zacks Investment ResearchPetro Global News 24Which Analysts Are Watching Bio-Path Holdings (BPTH)? – Fiscal …Fiscal Standardall 9 news articles »

Read More

Phase 3 FCS Trial Meets Primary Endpoint. Akcea to Begin Submission to FDA in 2017 – Rare Disease Report

Rare Disease ReportPhase 3 FCS Trial Meets Primary Endpoint. Akcea to Begin Submission to FDA in 2017Rare Disease ReportAkcea Therapeutics announced that the pivotal Phase 3 APPROACH study, testing the antisense drug volanesorsen, met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome (FCS). FCS is a rare genetic …

Read More

OPKO Health (OPK) Announces EU Designation for Orphan Drug Status for Oligonucleotide to Treat Genetic … – StreetInsider.com

OPKO Health (OPK) Announces EU Designation for Orphan Drug Status for Oligonucleotide to Treat Genetic …StreetInsider.comAntagoNAT, anti-Natural Antisense Transcripts, is an OPKO platform technology in which single strand oligonucleotide molecules are designed to interfere with regulatory gene expression in order to enhance production of endogenous functional proteins.and more »

Read More

Antisense Agent Promising in Rare Triglyceride Disorder – Medscape

MedscapeAntisense Agent Promising in Rare Triglyceride DisorderMedscapeCARLSBAD, CA and CAMBRIDGE, MA — In the 52-week phase 3 APPROACH study involving 66 patients, volanesorsen met its primary end point of significant reduction in triglycerides in patients with familial chylomicronemia syndrome (FCS), in early …Ionis slips as safety concerns offset efficacy in FCS phase 3FierceBiotechIonis Pharmaceuticals Inc (IONS) Files Form 4 Insider Selling : B …Energy IndexAkcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial …Canada NewsWire (press release)BioPharma Dive -The Pharma Letter (registration) -Seeking Alphaall 78 news articles »

Read More

Using spherical nucleic acids to track and treat disease

Spherical nucleic acids are structures that are made by taking a nanoparticle template and using chemistry to arrange short strands of DNA or RNA on the surface of those particles. The spherical core of the nanoparticle creates a spherical arrangement of DNA or RNA, similar to tiny little balls of nucleic acids.

Read More

New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharmaceutical Buck – Managed Care magazine

Managed Care magazineNew Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharmaceutical BuckManaged Care magazineMuscular dystrophy created a lot of news in 2016 with the controversial release of eteplirsen (Exondys 51), an antisense oligonucleotide indicated for a form of Duchenne muscular dystrophy. Exondys 51 was approved with considerable drama played out in …

Read More

Ionis Pharmaceuticals Inc (IONS) Releases Earnings Results, Beats Expectations By $0.51 EPS – Highland Mirror

The Cerbat GemIonis Pharmaceuticals Inc (IONS) Releases Earnings Results, Beats Expectations By $0.51 EPSHighland MirrorIonis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to …Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings February 28, 2017Zacks.comShares of Ionis Pharmaceuticals, Inc. (IONS) Plunge -5.01%Energy Indexall 46 news articles »

Read More

Idera Pharmaceuticals’ Well-Funded And Growing Pipeline Of Potentially Blockbuster Drug Candidates Offers … – Seeking Alpha

Seeking AlphaIdera Pharmaceuticals’ Well-Funded And Growing Pipeline Of Potentially Blockbuster Drug Candidates Offers …Seeking AlphaIdera starts 2017 with a clear strategy; it is well-funded, has a robust and growing pipeline, and expects to deliver powerful near-term catalysts. The company begins the year with over $100M in cash, which is enough to advance its diverse pipeline …Idera Pharmaceuticals, Inc. (IDRA) Given “Outperform” Rating at WedbushThe Cerbat GemShould You Buy Idera Pharmaceuticals, Inc. (IDRA) On Current Analyst Views?Fiscal Standardall 14 news articles »

Read More

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board – Yahoo Finance

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory BoardYahoo Finance21, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the …Analysts Update Their Price Target On Bio-Path Holdings (BPTH …UK Market Newsall 2 news articles »

Read More

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board – GlobeNewswire (press release)

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory BoardGlobeNewswire (press release)HOUSTON, Feb. 21, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer …and more »

Read More

Global Antisense and RNAi Therapeutics Market to grow at a Stunning CAGR of 26.79 percent by 2019 – Medgadget (blog)

Global Antisense and RNAi Therapeutics Market to grow at a Stunning CAGR of 26.79 percent by 2019Medgadget (blog)RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site …

Read More

Global Antisense and RNAi Therapeutics Market to grow at a CAGR of 26.79 percent by 2019 – Satellite PR News (press release)

Global Antisense and RNAi Therapeutics Market to grow at a CAGR of 26.79 percent by 2019Satellite PR News (press release)RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site …

Read More

Gene Therapy and Antisense Drugs Market 2017 Research In-Depth Analysis, Applications, Forecasts To 2025 – Satellite PR News (press release)

Gene Therapy and Antisense Drugs Market 2017 Research In-Depth Analysis, Applications, Forecasts To 2025Satellite PR News (press release)Antisense gene therapy is emerging as one of the most beneficial therapeutics for various diseases such as tumors, cancer etc. These newer therapies are based on increased knowledge of molecular events that lead to disordered cellular growth.and more »

Read More

Gene Therapy and Antisense Drugs Market 2017 Research In-Depth Analysis, Applications, Forecasts To 2025 – Satellite PR News (press release)

Gene Therapy and Antisense Drugs Market 2017 Research In-Depth Analysis, Applications, Forecasts To 2025Satellite PR News (press release)Antisense gene therapy is emerging as one of the most beneficial therapeutics for various diseases such as tumors, cancer etc. These newer therapies are based on increased knowledge of molecular events that lead to disordered cellular growth.and more »

Read More

Targeting Toxic Tau Clusters in Brain May Improve Symptoms in Alzheimer’s, Study Shows – Alzheimer’s News Today

Alzheimer’s News TodayTargeting Toxic Tau Clusters in Brain May Improve Symptoms in Alzheimer’s, Study ShowsAlzheimer’s News TodayResearchers designed a group of short molecules called antisense oligonucleotides (ASOs) that specifically bind to the tau gene and block its expression in neurons. In mice expressing the mutant P301S human tau — which produces high levels of a toxic …and more »

Read More

Ionis Earns $75M Milestone from Bayer for Progress of Antisense Drug Program – Genetic Engineering & Biotechnology News (press release)

Sports PerspectivesIonis Earns $75M Milestone from Bayer for Progress of Antisense Drug ProgramGenetic Engineering & Biotechnology News (press release)Ionis Pharmaceuticals will receive a $75 development milestone payment from Bayer, relating to the continued clinical development of the antisense drug IONIS-FXIRx and the start of a clinical program for a second antisense candidate, IONIS-FXI-LRx …Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and …Yahoo FinanceIsis Pharmaceuticals Inc.: Ionis Pharmaceuticals to Hold 2016 Financial Results Conference CallThe Wall Street TranscriptIonis nabs $75M payment from Bayer on advancement of two anti-clotting programsSeeking AlphaMorning Outlook -TheFounders Dailyall 30 news articles »

Read More